Mesenchymal Stromal Cells-Derived Extracellular Vesicles as Potential Treatments for Osteoarthritis
Pharmaceutics · 25.06.2023 · 15 (7) · 1814
DOI: 10.3390/pharmaceutics15071814 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 25.06.2023. Verfasst von Shunling Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Naval Medical University, Shanghai 200433, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Shanghai Rising-Star Program.
Abstract (Originalsprache)
Osteoarthritis (OA) is a degenerative disease of the joints characterized by cartilage damage and severe pain. Despite various pharmacological and surgical interventions, current therapies fail to halt OA progression, leading to high morbidity and an economic burden. Thus, there is an urgent need for alternative therapeutic approaches that can effectively address the underlying pathophysiology of OA. Extracellular Vesicles (EVs) derived from mesenchymal stromal cells (MSCs) represent a new paradigm in OA treatment. MSC-EVs are small membranous particles released by MSCs during culture, both in vitro and in vivo. They possess regenerative properties and can attenuate inflammation, thereby promoting cartilage healing. Importantly, MSC-EVs have several advantages over MSCs as cell-based therapies, including lower risks of immune reactions and ethical issues. Researchers have recently explored different strategies, such as modifying EVs to enhance their delivery, targeting efficiency, and security, with promising results. This article reviews how MSC-EVs can help treat OA and how they might work. It also briefly discusses the benefits and challenges of using MSC-EVs and talks about the possibility of allogeneic and autologous MSC-EVs for medical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Department of Orthopedics Trauma, Shanghai Zhongye Hospital, Shanghai 200941, China.
- Department of Pharmacy, Tianjin Rehabilitation Center of Joint Logistics Support Force, Tianjin 300110, China.
- Department of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
- Institute of Translational Medicine, Shanghai University, Shanghai 200444, China.
- Institute of Advanced Interdisciplinary Materials Science, Shanghai University, Shanghai 200444, China.
ORCID-Profile: Jinbo Zhang
Förderung
- National Natural Science Foundation of China
- the Shanghai Rising-Star Program
Zitieren
APA
Yuan, S., Li, G., Zhang, J., Chen, X., Su, J., & Zhou, F. (2023). Mesenchymal Stromal Cells-Derived Extracellular Vesicles as Potential Treatments for Osteoarthritis. Pharmaceutics, 15(7), 1814. https://doi.org/10.3390/pharmaceutics15071814
Vancouver
Yuan S, Li G, Zhang J, Chen X, Su J, Zhou F. Mesenchymal Stromal Cells-Derived Extracellular Vesicles as Potential Treatments for Osteoarthritis. Pharmaceutics. 2023;15(7):1814. doi:10.3390/pharmaceutics15071814
BibTeX
@article{Yuan2023,
author = {Yuan, Shunling and Li, Guangfeng and Zhang, Jinbo and Chen, Xiao and Su, Jiacan and Zhou, Fengjin},
title = {Mesenchymal Stromal Cells-Derived Extracellular Vesicles as Potential Treatments for Osteoarthritis},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {7},
pages = {1814},
doi = {10.3390/pharmaceutics15071814}
}
EUVIMED